Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1-γ autoantibodies in adult patients with myositis by Parkes, Joanna E et al.
RESEARCH ARTICLE Open Access
Genetic background may contribute to
the latitude-dependent prevalence
of dermatomyositis and anti-TIF1-γ
autoantibodies in adult patients with
myositis
Joanna E. Parkes1* , Simon Rothwell2, Alexander Oldroyd2,3,4, Hector Chinoy2,4,5, Janine A. Lamb1
and The Myositis Genetics Consortium (MYOGEN)
Abstract
Background: The prevalence of dermatomyositis (DM) versus DM and polymyositis (PM) combined has been
shown to be negatively associated with latitude. This observation has been attributed to increasing exposure to
ultraviolet (UV) light towards the equator. In this study, we investigated whether differing genetic background in
populations could contribute to this distribution of DM.
Methods: Case data derived from the MYOGEN (Myositis Genetics Consortium) Immunochip study (n = 1769) were
used to model the association of DM prevalence and DM-specific autoantibodies with latitude. Control data (n = 9911)
were used to model the relationship of human leucocyte antigen (HLA) associated with DM autoantibodies and DM or
PM single-nucleotide polymorphisms (suggestive significance in the Immunochip project, P < 2.25 × 10− 5) in
healthy control subjects with latitude. All variables were analysed against latitude using ordered logistic regression,
adjusted for sex.
Results: The prevalence of DM, as a proportion of DM and PM combined, and the presence of anti-transcription
intermediary factor 1 (anti-TIF1-γ) autoantibodies were both significantly negatively associated with latitude (OR
0.96, 95% CI 0.95–0.98, P < 0.001; and OR 0.95, 95% CI 0.92–0.99, P = 0.004, respectively). HLA alleles significantly
associated with anti-Mi-2 and anti-TIF1-γ autoantibodies also were strongly negatively associated with latitude
(OR 0.97, 95% CI 0.96–0.98, P < 0.001 and OR 0.98, 95% CI 0.97–0.99, P < 0.001, respectively). The frequency of five
PM- or DM-associated SNPs showed a significant association with latitude (P < 0.05), and the direction of four of
these associations was consistent with the latitude associations of the clinical phenotypes.
Conclusions: These results lend some support to the hypothesis that genetic background, in addition to UV
exposure, may contribute to the distribution of DM.
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Background
The idiopathic inflammatory myopathies (IIMs) are a
spectrum of rare and heterogeneous autoimmune dis-
eases causing inflammation and weakness of skeletal
muscle. Major clinical subgroups are polymyositis (PM)
and dermatomyositis (DM). The relative prevalence of
PM versus DM varies between populations, and it ap-
pears to be dependent on latitude; as latitude increases,
the relative prevalence of DM (i.e., DM/DM and PM
combined) decreases [1, 2]. This effect has been attrib-
uted to higher ultraviolet (UV) radiation levels increas-
ing the likelihood of the development of DM over PM
towards the equator, and also increasing the prevalence
of the DM-specific autoantibody anti-Mi-2 [2–4]. UV ra-
diation is thought to play a role in DM owing to skin
changes being more prominent on the sun-exposed parts
of the face, neck and shoulders, reports of photoaggrava-
tion of skin lesions and increased cutaneous photosensi-
tivity compared with healthy control individuals [5, 6].
UV radiation is used in phototherapy of skin conditions
such as psoriasis as well as being a major risk factor for
skin cancer owing to its suppression of the immune sys-
tem. UV radiation affects the immune system in various
ways, including DNA damage via production of ROS,
induction of cytokine signalling and induction of
T-regulatory cells [7]. Although thought to be linked to
the development of some autoimmune disorders, it is
unclear how UV radiation contributes to the pathogen-
esis of conditions such as DM [2].
Notably, latitude and UV radiation intensity do not
perfectly correlate, and UV exposure may depend on the
behaviour of individuals, such as whether they work in-
doors or outdoors. It is possible that the observed differ-
ences in DM, PM and anti-Mi-2 prevalence with latitude
could additionally be influenced by other factors, such as
the different genetic backgrounds of populations. The
most strongly associated single-nucleotide polymorph-
ism (SNP) outside the human leucocyte antigen (HLA)
gene complex for the PM subgroup in a recent IIM
Immunochip study (rs2476601 in PTPN22) [8] demon-
strates a correlation with latitude, with increasing risk al-
lele frequency from southern to northern Europe [9].
Similarly, some HLA allele frequencies are known to
vary with latitude, such as HLA-B27, associated with an-
kylosing spondylitis, which is absent in populations
around the equator but increases to 40% in populations
in the far north and the Arctic [10].
The aim of this study was to explore the associations
of PM and DM prevalence and autoantibody frequencies
with latitude. In particular, we investigated whether
these “latitude-dependent” associations could instead be
attributed to genetic background rather than environ-
mental factors by analysing the distribution of PM and
DM risk SNPs in healthy populations.
Methods
Association of relative prevalence of PM and DM, and DM
autoantibody frequency with latitude in a large myositis
cohort
Data from the IIM Immunochip study [8] were used to
model the association of relative prevalence of PM or
DM and DM-specific autoantibody frequency with
latitude. Of the DM-specific autoantibodies, only
anti-transcription intermediary factor 1-γ (anti-TIF1-γ)
(97 positive, 1345 tested) and anti-Mi-2 (83 positive,
1471 tested) were analysed, because only a limited
number of patients were anti-SAE- (n = 29) or
anti-MDA5-positive (n = 18). Autoantibodies were tested
in various centres using immunoprecipitation, line blot
or enzyme-linked immunosorbent assays. Geographical
latitude was assigned according to the approximate lati-
tude of the recruitment centre which contributed sam-
ples to the MYOGEN (Myositis Genetics Consortium)
Immunochip study as a proxy for latitude of origin and
disease onset [8]. Data were available from 1769 cases
(914 PM and 855 DM) from 12 countries worldwide
(Additional file 1). All individuals included in the study
were Caucasian. Juvenile cases were excluded because
some contributing centres collected only juvenile DM
cases, and this may have introduced bias into the latitu-
dinal associations.
Analysis of association of PM and DM single-nucleotide
polymorphism risk alleles with latitude in healthy control
subjects
The risk allele frequencies of ten SNPs associated with
PM or DM (suggestive significance threshold of P <
2.25 × 10− 5) in the Immunochip study [8] were analysed
for their association with latitude using the control indi-
viduals from the study (n = 9911). Recruitment centre
information was not available for some control individ-
uals; for these samples average latitude of the contribut-
ing country was used (see Additional file 1 for details).
U.S. control samples lacking recruitment centre infor-
mation were excluded owing to the large range of
possible latitudes.
Analysis of association of HLA alleles with DM-specific
autoantibodies with latitude in healthy control subjects
HLA alleles associated with DM-specific autoantibodies
also were analysed for their association with latitude in
the Immunochip control individuals (n = 9911). In the
Immunochip data HLA-DRB1* 07:01 is strongly associ-
ated with anti-Mi-2, and HLA-DQB1*02 is strongly asso-
ciated with anti-TIF1-γ (P = 4.36 × 10− 12 and P = 2.11 ×
10− 11 respectively [11], Rothwell S: Personal communi-
cation, in preparation). All associations were modelled
using ordered logistic regression, adjusted for sex.
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Analysis was carried out using STATA version 13.1 (Sta-
taCorp, College Station, TX, USA) [12].
Results
Relative prevalence of DM and frequency of anti-TIF1-γ
autoantibodies are significantly negatively associated
with latitude in adult myositis
In ordered logistic regression analysis using the IIM
Immunochip case data (n = 1769), the relative preva-
lence of DM (versus PM and DM combined) had a sig-
nificant association with latitude (OR 0.96, 95% CI 0.95–
0.98, P < 0.001) (Additional file 2). The presence of
anti-TIF1-γ autoantibodies in the cases tested (n = 1345)
was negatively associated with latitude (OR 0.95, 95% CI
0.92–0.99, P = 0.004). However, the presence of
anti-Mi-2 autoantibodies in the cases tested (n = 1471)
was not significantly associated with latitude (Table 1).
PM and DM SNP risk alleles are significantly associated
with latitude in healthy populations
In ordered logistic regression analysis using data from
the Immunochip study controls (n = 9911), the fre-
quency of four of eight PM-associated SNP risk alleles
showed a significant association with latitude (P < 0.05);
the three most significant associations were positively
associated. One of the two DM-associated SNPs was sig-
nificantly negatively associated with latitude (Table 2).
HLA alleles associated with DM-specific autoantibodies
are significantly associated with latitude in healthy
control individuals
In ordered logistic regression analysis using control
data from the IIM Immunochip study (n = 9911),
HLA alleles associated with the DM-specific autoanti-
bodies anti-Mi-2 and anti-TIF1-γ were strongly
negatively associated with latitude (OR 0.97, 95% CI
0.96–0.98, P < 0.001; and OR 0.98, 95% CI 0.97–0.99,
P < 0.001, respectively).
Discussion
In this study we analysed the associations between lati-
tude and DM relative prevalence and DM-specific auto-
antibody frequencies in the largest IIM cohort to date.
In addition, we analysed the association of latitude with
PM- or DM-associated SNP risk allele frequencies and
HLA alleles associated with DM autoantibodies in
healthy populations. The results confirmed that the pro-
portion of DM increases towards the equator, with a
strong negative association with latitude. Furthermore,
we showed, for the first time, to our knowledge, that
DM-specific anti-TIF1-γ autoantibody frequency was
significantly negatively associated with latitude along
with HLA alleles associated with anti-TIF1-γ and
anti-Mi-2. However, we failed to replicate the increase in
the presence of anti-Mi-2 autoantibodies towards the
equator which was reported in a previous study (P =
0.0349) [2]. The association of anti-Mi-2 with surface
UV radiation intensity in that study was more signifi-
cant (P = 0.0196) than the association with latitude
and later replicated in another study of UV radiation
[2, 3]. In addition, exposing keratinocytes to UV
radiation has been shown to increase the expression
of Mi-2 protein [13], supporting the hypothesis that
UV radiation may be associated with production of
anti-Mi-2 autoantibodies.
In the analysis of PM- and DM-associated non-HLA
SNP risk allele frequency, we found that half of the SNPs
analysed were significantly associated with latitude and
four of five were consistent with the latitude associations
of PM or DM prevalence (positive for PM and negative
for DM). Effect sizes were modest, but the ORs had tight
CIs and were statistically significant.
This study has some limitations, including the assump-
tion that the patients’ location at disease onset and place
of birth would be similar to the location of the recruit-
ment centres. The study was limited to one ethnic group
because the genetic association study was performed only
Table 1 Association of latitude with dermatomyositis prevalence, dermatomyositis-specific autoantibody and associated human leucocyte
antigen allele frequency
Variable Associations with latitude, adjusted for sex
OR (95% CI) P value
Relative prevalence of DM 0.96 (0.95, 0.98) < 0.001
Anti-Mi-2 0.99 (0.97, 1.03) 0.927
Anti-TIF1-γ 0.95 (0.92, 0.99) 0.004
HLA-DRB1*07:01 (associated with anti-Mi-2) 0.97 (0.96, 0.98) < 0.001
HLA-DQB1*02 (associated with anti-TIF1-γ) 0.98 (0.97, 0.99) < 0.001
DM Dermatomyositis, HLA Human leucocyte antigen, TIF1-γ Transcription intermediary factor 1
All variables were analysed against latitude in an ordered logistic regression analysis, adjusted for sex. Relative prevalence of DM was calculated as the frequency
of DM/the frequency of polymyositis (PM) and DM combined. The proportion of autoantibodies was calculated from all adult PM and DM cases tested for that
particular autoantibody (n = 1471 tested for anti-Mi-2, n = 1345 tested for anti-TIF1-γ), derived from case data in the Immunochip study (n = 1769). HLA allele
frequencies were calculated from the Immunochip control data (n = 9911) for DM-specific autoantibody associations in the Immunochip data (HLA-DRB1*07:01
with anti-Mi-2 and HLA-DQB1*02 with anti-TIF1-γ, P = 4.36 × 10− 12 and P = 2.11 × 10− 11, respectively [11]; Rothwell S: Personal communication, in preparation)
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in Caucasian samples. In addition, samples were collected
within a limited range of latitudes, and the cases and con-
trols were not from exactly the same populations. Studies
with collection of disease onset and place of birth data
along with UV exposure data in a larger multi-ethnic IIM
and control cohort spread over a greater range of latitudes
could elucidate whether latitude associations are due to
population genetic background or environmental factors.
Conclusions
Overall, these results lend some support to the hypoth-
esis that different genetic backgrounds of populations
may contribute to the increased prevalence of DM to-
ward the equator, in addition to, or instead of, increasing
UV radiation exposure levels.
Additional files
Additional file 1: Table S1. Immunochip study data included in analyses.
Assigned latitude and numbers of PM, DM and controls at each centre
included in the study. (DOCX 25 kb)
Additional file 2: Figure S1. The association of relative dermatomyositis
(DM) prevalence, frequency of DM-associated autoantibodies, HLA alleles
and single-nucleotide polymorphisms with latitude. Two-way linear
prediction plot with 95% CIs was produced using STATA version 13.1
software. Data for DM as a proportion of PM and DM (n = 1769), frequency
of anti-TIF1-γ in all samples tested (n = 1345) and frequency of anti-Mi-2 in
all samples tested (n = 1471) are derived from the Immunochip study [8].
Frequencies of HLA-DQB1*02, HLA-DRB1*07:01, rs4702698 and rs570676 are
derived from the Immunochip control data (n = 9911). (TIF 2203 kb)
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